Skip to main content
. 2016 Mar;13(1):77–86. doi: 10.28092/j.issn.2095-3941.2016.0008

Table2.

Selected RAS-targeted clinical trials

Drug Target Phase Study population Clinicaltrials.gov
Selumetinib MEK 3 Second line stage 4 or stage 3B NSCLC NCT01933932
MEK162+erlotinib MEK 1 Metastatic, failed prior therapies NCT01859026
Trametinib+momelotinib MEK+JAK1/2 1 Metastatic, progression after platinum based chemotherapy NCT02258607
PALBOCICLIB+PD-0325901 CDK4/6+MEK 1/2 Metastatic, failed prior therapies NCT02022982
AZD2014+selumetinib mTOR+MEK 1/2 Metastatic, failed prior therapies NCT02583542